FARN — Faron Pharmaceuticals Oy Share News
0.000.00%
Last trade - 00:00
- £139.15m
- £144.40m
REG - Faron Pharma. Oy - FDA Orphan Drug Designation for Bexmarilimab
AnnouncementREG - Faron Pharma. Oy - Notice of Half-Year Financial Results
AnnouncementRCS - Faron Pharma. Oy - Faron to Participate at Canaccord Conference
AnnouncementREG - Faron Pharma. Oy - Grant of Options
AnnouncementRCS - Faron Pharma. Oy - Faron to Hold BEXMAB Study Conference Call
AnnouncementREG - Faron Pharma. Oy - BEXMAB study update
AnnouncementREG - Faron Pharma. Oy - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 30/06/2023
AnnouncementREG - Faron Pharma. Oy - Announcement of Placing
AnnouncementREG - Faron Pharma. Oy - Exercise of options
AnnouncementRCS - Faron Pharma. Oy - New biomarker data from BEXMAB study at EHA2023
AnnouncementREG - Faron Pharma. Oy - Board Member to Assume Transactional Advisor Role
AnnouncementRCS - Faron Pharma. Oy - Bexmarilimab Efficacy and Safety in MATINS Trial
AnnouncementRCS - Faron Pharma. Oy - Bexmarilimab KOL Event
AnnouncementRCS - Faron Pharma. Oy - Poster Presentations at AACR 2023
AnnouncementREG - Faron Pharma. Oy - BEXMAB study update
AnnouncementRCS - Faron Pharma. Oy - Faron at Canaccord Oncology Virtual Conference
AnnouncementREG - Faron Pharma. Oy - Appointment of Chief Financial Officer
AnnouncementREG - Faron Pharma. Oy - Board Change
Announcement